Treating patients who have cancer with vaccines that stimulate a targeted immune response
is conceptually appealing, but cancer vaccine trials have not been successful in late-stage …

Effective anti-tumour immunity in humans has been associated with the presence of T cells
directed at cancer neoantigens, a class of HLA-bound peptides that arise from tumour …

Lymphoid organs, in which antigen presenting cells (APCs) are in close proximity to T cells,
are the ideal microenvironment for efficient priming and amplification of T-cell responses …

Personal neoantigen vaccines have been envisioned as an effective approach to induce,
amplify and diversify antitumor T cell responses. To define the long-term effects of such a …

Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses,–; however, the relationship between phenotypic …

The immune system influences the fate of developing cancers by not only functioning as a
tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts …

T cells directed against mutant neo-epitopes drive cancer immunity. However, spontaneous
immune recognition of mutations is inefficient. We recently introduced the concept of …

Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low
immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease …

With the advent of checkpoint blockade therapies, immunotherapy is now a critical modality
for the treatment of some cancers. While some patients respond well to checkpoint blockade …

Great progress has been made in the field of tumor immunology in the past decade, but
optimism about the clinical application of currently available cancer vaccine approaches is …